Granulox® was found to be more effective and less costly than standard care.
Three retrospectively controlled cohort studies in patients with diabetic foot ulcers (n=20, active treatment), chronic wounds (n=50) and sloughy wounds (n=100) reported improved wound healing outcomes over a 6 month follow-up. At final follow-up 15 out of 20 diabetic foot ulcer patients treated with Granulox® had complete healing compared to 8 out of 20 controls.
What were we asked to look at?
We were asked to provide a high level overview of Granulox technology.
Granulox® haemoglobin spray is a Class III medical device indicated for the treatment of chronic wounds, such as venous leg ulcers, arterial leg ulcers, mixed leg ulcers, diabetic foot ulcers, secondary healing of surgical wounds and pressure sores.
Why is this important?
There is a significant burden of a wound on patients’ daily lives; from the physical impact, the psychological impact, to the restrictions on lifestyle. The manufacturer proposes the use of Granulox® for the treatment of chronic venous leg ulcers which have failed to heal with standard care. Granulox® is an add-on treatment option to standard care.